INFI - Infinity Pharmaceuticals - Stock Forecast

Healthcare - Sector
Coverage Stock analysts Price Targets & Ratings Chart Insider Trading

Infinity Pharmaceuticals's activity chart (see below) currently has 32 price targets and 32 ratings on display.

Stock Analyst Price Targets - Review

Analysts average stock forecasts to be materialized ratio is 32.89% with an average time for these price targets to be met of 121 days.

Most recent stock forecast was given by from PIPER SANDLER on 24-Feb-2023.

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date of last PT

Price targets met ratio

Average potential upside

Average Days to Hit Target

Performance score

Buy Since 18-Feb-2021

$3

3 years 8 months ago
(24-Feb-2023)

0/3 (0%)

$2.38 (383.87%)

Buy Since 28-Jul-2021

$3

3 years 11 months 8 days ago
(16-Nov-2022)

0/3 (0%)

$1.97 (191.26%)

Buy Since 17-Mar-2021

$12

4 years 2 months 12 days ago
(12-Aug-2022)

0/1 (0%)

$8.8 (275.00%)

Buy Since 07-May-2015

$4

4 years 6 months 23 days ago
(31-Mar-2022)

0/3 (0%)

$2.87 (253.98%)

$6

$6 (0.00%)

5 years 2 months 22 days ago
(02-Aug-2021)

0/1 (0%)

$3.07 (104.78%)

Show more analysts

Please expand the browser size to see the chart

What is INFI (Infinity Pharmaceuticals) average time for price targets to be met?

On average it took 121 days for the stock forecasts to be reached, with an average price target met ratio of 32.89%.

Which analyst most recently updated their price target on INFI (Infinity Pharmaceuticals)?

Which analyst has the most public recommendations on INFI (Infinity Pharmaceuticals)?

has 0 price targets and 0 ratings on INFI

Which analyst is the currently most bullish on INFI (Infinity Pharmaceuticals)?

Ian Somaiya with the highest potential upside of $13

Which analyst is the currently most reserved on INFI (Infinity Pharmaceuticals)?

Edward Tenthoff with the lowest potential downside of -$0
✖

To continue looking at which analysts cover the stock please register to the basic or advanced membership

To continue looking at analysts data please register to the advanced membership

What is AnaChart?